Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25615684 | 0.80 | ANPEP (0.36) | CYP2C19MMP8ALDH1A1 | |
| SCHEMBL17552353 | 0.79 | CYP2D6 (0.37) | CYP2D6CYP2C19MMP1MMP8ALDH1A1 | |
| SCHEMBL22649508 | 0.77 | GRIN2D (0.34) | — | |
| SCHEMBL16259082 | 0.77 | CYP2D6 (0.38) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL25226890 | 0.76 | — | — | |
| SCHEMBL13946652 | 0.76 | — | — | |
| SCHEMBL13066386 | 0.76 | — | — | |
| SCHEMBL17536206 | 0.75 | POLB (0.32) | — | |
| SCHEMBL20643445 | 0.75 | POLB (0.32) | — | |
| SCHEMBL17536205 | 0.75 | POLB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11180425-B2 | Compositions for increasing nitrogen sources life span in plant growth mediums and methods of making | SOILGENIC TECHNOLOGIES, LLC | 2021-11-23 | — | — | US | disclosed |
| US-20210340074-A1 | REACTION PRODUCTS AND METHODS FOR MAKING AND USING THE SAME | KOCH AGRONOMIC SERVICES, LLC | 2021-11-04 | — | — | US | disclosed |
| US-11028024-B2 | Reaction products and methods for making and using the same | KOCH AGRONOMIC SERVICES, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20200024205-A1 | Compositions for Increasing Nitrogen Sources Life Span in Plant Growth Mediums and Methods of Making | SOILGENIC TECHNOLOGIES, LLC | 2020-01-23 | — | — | US | disclosed |
| US-20190124917-A1 | MICROBIAL INOCULANT COMPOSITIONS AND USES THEREOF | KOCH AGRONOMIC SERVICES, LLC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190112240-A1 | REACTION PRODUCTS AND METHODS FOR MAKING AND USING THE SAME | KOCH AGRONOMIC SERVICES, LLC (US) | 2019-04-18 | — | — | US | disclosed |
| US-10239799-B2 | Reaction products and methods for making and using the same | KOCH AGRONOMIC SERVICES LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-9403763-B2 | CD4-mimetic inhibitors of HIV-1 entry and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-02 | — | — | US | disclosed |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | CYP2D6 2783/4885CYP2C19 2303/4885MMP1 3482/4885 |
| US-20190124917-A1 | MICROBIAL INOCULANT COMPOSITIONS AND USES THEREOF | NUDT5, UMPS, NT5E | CYP2D6 1778/4885CYP2C19 1084/4885MMP1 967/4885 |
| US-20140350113-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD14, CCR5 | CYP2D6 1986/4885CYP2C19 3337/4885MMP1 4562/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP2D6 4714/4885CYP2C19 4869/4885MMP1 4279/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | CYP2D6 4277/4885CYP2C19 4203/4885MMP1 638/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | CYP2D6 706/4885CYP2C19 1586/4885MMP1 366/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3178/4885CYP2C19 3930/4885MMP1 4721/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3178/4885CYP2C19 3930/4885MMP1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.